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Abstract Entacapone is frequently used together with
levodopa/carbidopa (LC) and levodopa/benserazide (LB)
in the treatment of Parkinson’s disease (PD) patients with
wearing-off symptoms. It is generally assumed that the
effects of entacapone are independent of the type of
decarboxylase inhibitor used, but there is very little pub-
lished data available on the efficacy of entacapone
administered with LB versus LC. We have performed a
pooled analysis of three randomized, double-blind,
6-month, phase III studies to compare the treatment effects
of entacapone (compared to placebo) in PD patients
receiving LC or LB. A total of 551 PD patients experi-
encing wearing-off were included in the analysis. 300
patients were on LB and 251 on LC at baseline. At
6 months, entacapone (compared to placebo) improved
mean daily OFF-time in patients on LB and LC by 0.76
(p = 0.016) and 0.95 (p = 0.011) hours, respectively. The
corresponding improvements in ON-time were 0.97
(p = 0.002) and 0.83 h (p = 0.022), respectively. The
treatment effects of entacapone both in LB and LC users
were statistically significant (p\ 0.05) also in UPDRS II
and III scores, except in UPDRS II scores in patients
receiving LC (p = 0.20). None of the treatment effects of
entacapone were statistically significantly different
between patients receiving LB or LC. Reported adverse
events were comparable between LB and LC users. We
conclude that entacapone provided comparable benefits in
PD patients with wearing-off symptoms using either LB or
LC.
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Introduction
After more than 40 years of routine clinical use levodopa
has remained the gold standard of symptomatic efficacy in
the treatment of Parkinson’s disease (PD). Levodopa is
always combined with a dopa-decarboxylate inhibitor
(DDCI) and current preparations either use carbidopa or
benserazide to block the main levodopa metabolizing
enzyme. Earlier randomized, controlled studies in PD
patients have reported that the clinical effects and levodopa
pharmacokinetics (PK) are comparable between carbidopa
and benserazide (Greenacre et al. 1976; Pakkenberg et al.
1976; Rinne and Mo¨lsa¨ 1979).
Adjunct therapy with a catechol-O-methyltransferase
(COMT) inhibitor is a first-line strategy when treating PD
patients who have developed wearing-off with
levodopa/carbidopa (LC) or levodopa/benserazide (LB).
Entacapone and tolcapone are the two COMT-inhibitors
currently available. Both increase the bioavailability of
levodopa combined with carbidopa (Kera¨nen et al. 1993;
Sedeˆk et al. 1997) and benserazide (Kaakkola et al. 1994;
Dingemanse et al. 1995) and thereby prolonging clinical
response (Nutt et al. 1994; Kaakkola et al. 1994, 1995;
Baas et al. 1997).
Randomized, double-blind, placebo-controlled phase III
trials have confirmed the efficacy of entacapone in reduc-
ing OFF-time in PD patients with wearing-off compared to
placebo (PSG 1997; Rinne et al. 1998; Poewe et al. 2002;
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Brooks and Sagar 2003). In three of these studies (Rinne
et al. 1998; Poewe et al. 2002; Brooks and Sagar 2003),
patients were receiving either LC or LB while in the fourth
study (PSG 1997) all patients received LC. These data were
analysed for the entire study populations, not separately for
patients on LC or LB, thus there are very little published
data on the efficacy and safety of entacapone specifically in
patients using LB. We were able to identify only one small
study conducted in nine wearing-off patients (Kaakkola
et al. 1994), which reported increased plasma AUC of
levodopa and improved motor disability after starting
entacapone as add-on to each dose of LB.
Here we have pooled data from three phase III enta-
capone trials, which recruited patients both on LC or LB.
The aim of the analysis was to evaluate the efficacy and
safety of entacapone (compared with placebo) separately
for patients receiving LC and LB and to compare the
treatment effect of entacapone between patients on the two
DDC-inhibitors.
Materials and methods
This was a retrospective, pooled analysis of three ran-
domized, double-blind, placebo-controlled, 6-month, phase
III studies in PD patients with wearing-off (Rinne et al.
1998; Poewe et al. 2002; Brooks and Sagar 2003 including
patients both on LC or LB. Patients’ antiparkinsonian
medications (especially levodopa) were individually opti-
mized before randomization. Other antiparkinsonian med-
ications were allowed, but doses were not to be changed
during the studies. The phase III study conducted by the
Parkinson Study Group (PSG 1997) was left out from the
dataset, because it did not include any patients receiving
LB.
A pooled analysis is similar to a traditional meta-anal-
ysis, however, outcome measures and other data are com-
bined from multiple studies and are analysed as a single
dataset. This pooled analysis was possible due to access to
the raw data from studies with similar study design and
efficacy variables (ON/OFF-time by home diary and
UPDRS scores). Two of the original studies also included
non-fluctuating patients (Poewe et al. 2002; Brooks and
Sagar 2003) and these patients were excluded from the
present dataset. There was a small number of patients using
both LC and LB (mixed users) and they were also excluded
from the analysis. In all studies, patients on LC or LB were
randomized to receive either entacapone or placebo.
Efficacy variables were daily ON- and OFF-times
recorded by patient diary (collected as 18 or 24 h diaries
and standardized to18 h) and Unified Parkinson’s Disease
Ratings Scale (UPDRS) part II (ADL) and III (motor)
scores. The original studies were conducted in 1993–1998.
During that time, patient diaries included only variables of
‘ON’, ‘OFF’ or ‘IN BED’. UPDRS III scores were assessed
during ON-state and UPDRS II scores reflected patient’s
daily functioning over a preceding week without specifying
between ON- and OFF- states. ON- and OFF-times,
UPDRS scores and mean daily levodopa doses were
analysed using the intention-to-treat datasets of each orig-
inal study with observed cases (ITT-OC). Analysis of
covariance (ANCOVA) models with fixed effects for
treatment (entacapone or placebo), DDCI group (LB or
LC) and their interaction were used to estimate the dif-
ference between entacapone and placebo within the LB and
LC treated patients and the difference in the treatment
effect (entacapone vs placebo) between the LB and LC
treated patients. Baseline value was used as a covariate. All
efficacy results are reported as changes from baseline at
6 months (24 weeks) estimated with the ANCOVA model.
No correction for multiple comparisons was done. All the
statistical analyses were performed using the SAS soft-
ware version 9 (SAS Institute Inc., Cary, NC, USA).
The safety was evaluated by adverse events (AEs). All
AEs were coded with World Health Organization Adverse
Reactions Terminology (WHO-ART) and the proportions
of patients in each group reporting treatment-emergent AEs
up to 6 months were summarized by the preferred term. All
AEs reported in at least one group by at least 3 % of the
patients are reported. The incidences of AEs were analysed
using a logistic regression model including terms for
treatment group (entacapone or placebo), DDCI (LB or
LC) and their interaction.
Each original study was performed according to good
clinical practice, reviewed by the local ethics committee
and approved by the relevant national competent authori-
ties. All subjects gave their informed consent.
Results
Baseline demographics
A total of 551 PD patients experiencing wearing-off were
included in the ITT analysis, of which 300 patients were on
LB and 251on LC at baseline. A total of 336 and 215
patients were randomized to entacapone and placebo,
respectively. In the LB group, 170 and 130 patients were
randomized to entacapone and placebo, respectively. The
respective numbers of randomized patients in the LC group
were 166 and 85. The safety dataset was identical to the
dataset used for the ITT analysis.
At baseline in the total study population, the mean (SD)
age was 62.8 (9.3) years, duration of PD 9.6 (5.0) years,
duration of levodopa treatment 8.0 (4.6) years, daily
levodopa dose 646 (328) mg and daily OFF-time 5.9
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(2.4) h. There were no significant differences in baseline
characteristics between patients receiving LB or LC
(Table 1).
Efficacy
At 6 months, a significant decrease in mean OFF-time in
LB (-0.76 h; 95 % confidence interval (CI) from -1.37 to
-0.15 h; p = 0.016) and LC (-0.95 h; 95 % CI from
-1.67 to -0.23 h; p = 0.011) groups was seen in patients
randomized to entacapone compared with those receiving
placebo. The respective increases in ON-time were 0.98 h
(0.36–1.59 h; p = 0.002) and 0.82 h (0.09–1.55 h;
p = 0.022) for LB and LC, respectively. Treatment effects
of entacapone did not differ significantly between patients
on LB or LC regarding OFF- (p = 0.692) and ON-times
(p = 0.762) (Fig. 1).
The improvements in mean (95 % CI) UPDRS part II
scores in patients receiving entacapone were -1.1 (-2.0 to
-0.2); p = 0.016) and -0.7 (-1.7 to 0.4); p = 0.203)
compared with placebo in patients on LB and LC,
respectively. In turn, entacapone improved mean (95 % CI)
UPDRS part III scores by -2.2 points (-4.2 to -0.2);
p = 0.036) and -2.6 points (-5.0 to -0.3); p = 0.031)
compared with placebo in LB and LC users, respectively.
The treatment effects of entacapone in UPDRS part II
(p = 0.522) and part III (p = 0.775) scores were not dif-
ferent between LB and LC users (Fig. 2).
Mean (95 % CI) daily levodopa dose decreased signif-
icantly during the 6-month follow-up in LB and LC
patients randomized to entacapone by -82 mg (-120 to
-45); p\ 0.001) and -52 mg (-95 to -9); p = 0.020),
respectively. The treatment effects were not significantly
different (p = 0.294) between patients on LB and LC.
Tolerability and safety
Entacapone was generally well tolerated in patients on LB
or LC. The most commonly reported AEs (preferred term)
for entacapone were dyskinesia, diarrhea, hyperkinesia,
nausea, constipation and hypokinesia. Among those
receiving entacapone, 4 patients (2.4 %) on LB and and 3
patients (1.8 %) on LC discontinued the study due to
diarrhea. In the placebo group, the respective numbers
were 1 (0.8 %) and 0 patients. All the AEs reported at least
in 3 % of patients in the entire study population are pre-
sented in Table 2. No statistically significant interactions
between entacapone treatment and DDCI were seen for the
commonly reported AEs.
Discussion
This is the largest pooled analysis of the efficacy and safety
of entacapone specifically in patients on LB including a
total of 300 patients of which 170 and 130 were












Age (years) 61.8 (9.0) 62.3 (9.2) 63.9 (9.5) 63.3 (9.5) 62.8 (9.3)
Gender (male/female, %) 55/45 54/46 63/37 62/38 58/42
Duration of Parkinson’s Disease
(years)
9.2 (5.1) 10.4 (5.1) 9.0 (4.9) 10.2 (5.1) 9.6 (5.0)
Duration of L-dopa treatment
(years)
7.6 (4.4) 8.5 (4.4) 7.6 (4.6) 8.7 (4.9) 8.0 (4.6)
Hoehn and Yahr staging (B2/
C2.5, %)
45/55 52/48 37/63 39/61 43/57
Levodopa dose (mg) 626 (320) 630 (289) 645 (327) 717 (391) 646 (328)
Dopamine agonist users (%) 56 55 60 60 57
MAO-B inhibitor users (%) 48 49 45 41 46
Amantadine users (%) 13 14 21 13 15
Anticholinergic users (%) 17 15 13 17 15
Other antiparkinsonian
medication users (%)
1 1 1 0 1
OFF time (h) 6.1 (2.4) 5.8 (2.5) 5.6 (2.3) 5.8 (2.5) 5.9 (2.4)
UPDRS part III at ON state 25.1 (13.1) 24.3 (12.4) 23.8 (12.0) 24.3 (12.1) 24.4 (12.5)
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randomized to entacapone and placebo, respectively.
Entacapone significantly improved daily OFF- and ON-
times as well as UPDRS II and III scores irrespective of the
DDCI (carbidopa or benserazide) combined with levodopa.
These results are well in line with separate reports and the
overall pooled analysis of entacapone phase III studies
(PSG 1997; Rinne et al. 1998; Poewe et al. 2002; Brooks
and Sagar 2003; Kuoppama¨ki et al. 2014). An important
finding was also that the treatment effects of entacapone
(vs placebo) did not differ between patients on LC or LB.
In other words, patients on LB received similar benefits of
entacapone for the treatment of their wearing-off symp-
toms compared to those on LC. As the present analysis was
based on data from a pooled dataset, the analysis was not
prospectively powered for hypothesis testing and can
therefore be considered as explorative. For the comparison
of OFF-time difference between the two DDCIs, the
analysis had 92 % power to show a difference of 1.5 h in
daily OFF-time as statistically significant with a two-sided
significance level of 0.05 and assuming the observed
standard deviation of 2.5 h based on a test for the inter-
action term between randomized treatment group and
DDCI. This suggests that despite lack of a prospective
sample size calculation, the analysis is adequately powered
to detect clinically meaningful treatment effects. Tolera-
bility and safety of entacapone was also comparable
between patients on LC or LB.
Entacapone has become available as a separate product
and as a triple combination of levodopa/carbidopa/enta-
capone (LCE), the latter type of combination not being
available with benserazide. Nevertheless, an open-label,
6-week study has reported that patients on LB experienced
clinically relevant improvements in their condition when
switching directly from LB to LCE. The study also found
that the efficacy and safety of switching from LB to LCE


































Fig. 1 Changes in daily ON- and OFF-times in patients randomized
to entacapone or placebo and using levodopa/benserazide (LB) or
levodopa/carbidopa (LC). a ON-time and b OFF-time. Bars represent
estimated mean changes with standard error of mean (SEM); ITT-OC
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Fig. 2 Changes in UPDRS II and III scores in patients randomized to
entacapone or placebo and using levodopa/benserazide (LB) or
levodopa/carbidopa (LC). a UPDRS II and b UPDRS III. Bars
represent estimated mean changes with standard error of mean
(SEM); ITT-OC (intent to treat observed cases). Black bars
entacapone; white bars placebo. UPDRS Unified Parkinson’s Disease
Rating Scale
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et al. 2010). This finding is also in agreement with our
present analysis.
In conclusion, using a pooled analysis of three phase III
entacapone studies, we are reporting that adding entacapone
provided comparable benefits to PD patients on either LC or
LB when treating their wearing-off symptoms. To our
knowledge, this is the largest dataset reporting the efficacy
and safety of entacapone in PD patients receiving LB.
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